Decision Resources Group (DRG) estimates that 80% of the more than 3 million diagnosed prevalent cases of schizophrenia within our surveyed markets (i.e., United States, France, Germany, and United Kingdom) suffer from comorbid cognitive impairment, which can negatively affect patients’ quality of life and ability to function independently. No pharmacological agents are approved specifically for the treatment of cognitive impairment associated with schizophrenia (CIAS), and of the more than 30 antipsychotic therapies prescribed to treat the “core” psychiatric symptoms of schizophrenia, none offer therapeutic benefits for cognitive deficits. Although DRG research indicates that cognition-enhancing therapies and stimulants marketed for other diseases (e.g., Alzheimer’s disease, sleep disorders) may sometimes be prescribed off-label adjunct to an antipsychotic regimen to treat symptoms of CIAS, these drugs have accumulated negative or inconclusive clinical data from trials in CIAS patients. Thus, high unmet need and commercial opportunity exist for an efficacious therapy to treat CIAS in this underserved schizophrenia segment.


Related Reports

Schizophrenia - Landscape & Forecast - Disease Landscape And Forecast G7

The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are al...

View Details

Schizophrenia| Disease Landscape and Forecast | G7 | 2020

The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are also ava...

View Details

Schizophrenia - Special Topics - Special Topics Evolving Market Dynamics In Schizophrenia US

The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primaril...

View Details

Schizophrenia - Special Topics - Special Topics: Agitation In Bipolar And Schizophrenia (US)

Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or...

View Details